<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01612052</url>
  </required_header>
  <id_info>
    <org_study_id>1997028</org_study_id>
    <nct_id>NCT01612052</nct_id>
  </id_info>
  <brief_title>Vascular Surgical Antibiotic Prophylaxis Study (VSAPS 2)</brief_title>
  <official_title>Double Blinded Prospective Randomized Controlled Trial Comparing Cefazolin Plus Vancomycin Versus Cefazolin Plus Daptomycin for Vascular Surgery Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CAMC Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CAMC Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current recommended antibiotic, Cefazolin, treatment for vascular surgery, provides&#xD;
      coverage only for Methicillin-Sensitive Staphylococcus Aureaus (MSSA), other gram-positive&#xD;
      bacteria, and some gram-negative bacteria which may not be adequate antibiotic treatment at&#xD;
      the time of vascular surgery and result in an increased hospital length of stay, increased&#xD;
      cost of care, and an increased risk of morbidity and mortality as a consequence of surgical&#xD;
      site infections. Thus, the investigators want to compare whether Methicillin-resistant&#xD;
      Staphylococcus Aureaus (MRSA) antibiotic prophylaxis with Cefazolin plus Daptomycin is&#xD;
      superior to Cefazolin plus Vancomycin in the reduction of surgical site infection (SSI)&#xD;
      following open arterial revascularization procedures requiring a groin plus lower extremity&#xD;
      incision. The investigators hypothesis is that Cefazolin plus Daptomycin is superior to&#xD;
      Cefazolin plus Vancomycin in the prevention of SSI for high risk patients undergoing open&#xD;
      groin plus lower extremity procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is an increase in surgical site infection (SSI) due to MRSA. The current recommended&#xD;
      antibiotic, Cefazolin, treatment for vascular surgery, provides coverage only for&#xD;
      Methicillin-Sensitive Staphylococcus Aureaus (MSSA), other gram-positive bacteria, and some&#xD;
      gram-negative bacteria. To demonstrate that MRSA coverage is needed in vascular surgery with&#xD;
      prosthetic graft placement in areas of the body that is at high risk for infection, the&#xD;
      investigators are initiating a second study of patients undergoing groin plus lower extremity&#xD;
      procedures by using combination antibiotics such as Cefazolin plus Daptomycin, Cefazolin plus&#xD;
      Vancomycin. By decreasing post surgical site and prosthetic infections, the investigators&#xD;
      could significantly reduce vascular surgery mortality and morbidity. Cost and amputation&#xD;
      rates the investigators feel could also be reduced. Patients will be randomized in two groups&#xD;
      -- Cefazolin plus Daptomycin, Cefazolin plus Vancomycin and will be evaluated during post&#xD;
      procedure before discharge or within 30 days and between 30 and 360 days, for postoperative&#xD;
      complications including cellulitis, graft infection, sepsis, limb loss, graft failure, and&#xD;
      length of stay. If a patient is re-hospitalized, reason for the return and whether it is&#xD;
      related to the procedure will be evaluated. Additionally, is there a graft failure,&#xD;
      amputation, infection, hematoma, pseudoanurysm will be assessed. In case of a wound&#xD;
      infection, the type of organism and finally, length of this hospitalization will be recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference between number of patients with MRSA infection between two groups</measure>
    <time_frame>post procedure at 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference between number of patients with post-op complications between two groups</measure>
    <time_frame>post procedure at 360 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>MRSA - Methicillin Resistant Staphylococcus Aureus Infection</condition>
  <arm_group>
    <arm_group_label>Cefazolin plus Daptomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cefazolin plus Vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic Prophylaxis</intervention_name>
    <description>Comparing the antibiotic treatment related to surgery</description>
    <arm_group_label>Cefazolin plus Daptomycin</arm_group_label>
    <arm_group_label>Cefazolin plus Vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than 18 years&#xD;
&#xD;
          -  Any elective arterial revascularization procedure involving one or more groin plus&#xD;
             lower extremity incisions&#xD;
&#xD;
          -  Further, patient's considered at high risk because of history of MRSA colonization or&#xD;
             infection, HIV, admission for &gt;3 months in an acute care center or long-term care&#xD;
             center will be included in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with an allergy to Cefazolin, Daptomycin or Vancomycin.&#xD;
&#xD;
          -  Patients allergic to Penicillin.&#xD;
&#xD;
          -  Patients enrolled in another IRB approved biomedical study.&#xD;
&#xD;
          -  Patients with active infection requiring antibiotics preoperatively.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Stone, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAMC Medical Staff-with admitting privileges</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Stone, M.D.</last_name>
    <phone>304-388-8250</phone>
    <phone_ext>9901</phone_ext>
  </overall_contact>
  <location>
    <facility>
      <name>Vascular Center of Excellence</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Stone, M.D.</last_name>
      <phone>304-388-8250</phone>
      <phone_ext>9901</phone_ext>
    </contact>
    <investigator>
      <last_name>Steven Hass, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Albier Mousa, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ali F AbuRhama, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>September 1, 2011</study_first_submitted>
  <study_first_submitted_qc>June 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <last_update_submitted>February 18, 2013</last_update_submitted>
  <last_update_submitted_qc>February 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CAMC Health System</investigator_affiliation>
    <investigator_full_name>Patrick Stone, MD</investigator_full_name>
    <investigator_title>CAMC Medical Staff-with admitting privileges</investigator_title>
  </responsible_party>
  <keyword>Vascular Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 16, 2020</submitted>
    <returned>February 28, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

